Navigation Links
Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies
Date:7/1/2020

Psilera Bioscience (“Psilera”), a Florida based biotechnology LLC specializing in the clinical development of psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie Salm and Chris Witowski have 20+ years combined experience in natural product drug discovery, novel formulations, and as distinguished researchers within the cannabis industry. They are joined by pharmaceutical and corporate leaders alongside an extensive network of scientific and medical advisors.

“Problems relating to mental health are a growing concern, and the hardships created by COVID-19 have only exacerbated issues with depression, anxiety, and substance abuse,” said Dr. Chris Witowski, CEO of Psilera. “Therapeutic innovations have stagnated in these areas while cognitive disorders such as Alzheimer’s disease also lack effective treatment options. We are only scratching the surface of the medical potential for psychedelics and Psilera’s model of compassion-driven science will enable groundbreaking research to provide new therapies for patients in need.”

Psilocybin, the psychoactive ingredient found in some mushroom species, acts on the serotonin system but unlike other antidepressants only a few doses are needed for long-term benefits. This finding will increase acceptance of psychotherapies, while their ability to disrupt preconditioned thinking and improve cognition will provide Psilera a significant clinical pipeline for future discoveries. Psilera has accelerated research and development efforts and submitted a provisional patent covering new chemical entities and delivery methods relating to psychedelics.

“Psilera was built with the common goal to create mindful medicine with inspirations from nature and a foundation of innovative science,” said Dr. Jackie Salm, CSO of Psilera. “Our goal is to pave the way for a new era in psychedelics research and truly recognize the potential of these compounds as medicines. This requires detailed assessment of structure activity relationships and novel ways of delivery. We hope to increase awareness and shift the paradigm to a place of knowledge rather than fear.”

About Psilera Bioscience

Psilera Bioscience is a psychedelic-based biotechnology company developing its proprietary neuromodulator pipeline to target cognitive, mood, and addiction disorders. Psilera leverages research strengths with executives from the pharmaceutical and cannabis industries to repurpose psychoactive natural products as building blocks for next generation therapies to improve mental health.

Read the full story at https://www.prweb.com/releases/psilera_bioscience_announces_award_winning_executive_team_and_flagship_patent_milestone_for_future_psychedelic_therapies/prweb17230749.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. Dunn Foundation awards bioscience grants
2. Quincy Bioscience Promotes Older Driver Safety Awareness Week
3. Quincy Bioscience Announces the Kickoff of the Prevagen Blog
4. Crescendo Bioscience to present multiple studies at 2014 EULAR Meeting
5. Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide
6. Quincy Bioscience Launches the Second E-Book of the Making Memories Series
7. Quincy Bioscience Recognized in Inc. 500
8. 5000 List of America’s Fastest Growing Companies for Third Consecutive Year
9. ACEA Biosciences, Inc. to be featured in Upcoming Episode of Innovations with Ed Begley, Jr.
10. Quincy Bioscience Promotes National Self-Improvement Month
11. Creative Bioscience Releases Quality Assurance Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... , ... August 04, 2020 , ... Today, Power to ... Child Health Programs (AMCHP) with the 2020 Innovation Station Best Practice Award. The One ... and under what circumstances to get pregnant and have a child. One Key Question ...
(Date:8/3/2020)... ... 2020 , ... WorkBook6 – a Tempe, Arizona-based partnership development ... provides a simple and efficient way for Americans over the age of 65 ... important expansion for the insurance marketing ecosystem, and a critical service for seniors ...
(Date:8/3/2020)... CHICAGO and FORT WORTH, Texas (PRWEB) , ... ... ... clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line ... arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). ...
(Date:7/31/2020)... ... July 31, 2020 , ... ... patients to The Dental Studio of Midland for groundbreaking laser dentistry treatment ... result, these patients are able to experience the many advantages of laser dentistry ...
(Date:7/31/2020)... ... 2020 , ... National Association of Chain Drug Stores (NACDS) ... nation’s ongoing preparations for the eventual deployment of COVID-19 vaccines: , “By any ... essential component of vaccine deployment. They will need to be part of the ...
Breaking Medicine News(10 mins):
(Date:8/9/2020)... , ... August 09, 2020 , ... ... on sustainable results, today announced that Lydia C. Alexander, MD, has joined the ... medicine specialist, Dr. Alexander will play a vital role in expanding Enara Health’s ...
(Date:8/7/2020)... SEATTLE (PRWEB) , ... August 07, 2020 , ... ... sleep, published a literature review showing how sleep is a mechanism connecting social ... looked at the CDC’s survey of close to 444,000 Americans that draws direct ...
(Date:8/7/2020)... , ... August 07, 2020 , ... ... a blog educating readers on what intensive outpatient programs are and ... and to overcome their addiction, many turn to intensive outpatient programs provided by ...
Breaking Medicine Technology: